ReviewClinical transplantation and research2026
The Asian perspective on xenotransplantation: bridging the organ gap through regional collaboration and tailored clinical protocols.
Review in Clinical transplantation and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xenotransplantation using genetically engineered porcine organs has emerged as a transformative strategy to address the critical organ shortage crisis in Asia, where low deceased donation rates and high disease burden create a persistent supply-demand gap. This review examines the Asian perspective on xenotransplantation across five domains: sociocultural acceptance, technical advances in multigene-edited pig platforms, clinical protocol optimization for Asian recipients, regulatory harmonization through the Asian Xenotransplantation Association, and infrastructure development including hybrid clinical centers and capacity-building initiatives. Asian countries, particularly China, South Korea, and Japan, have demonstrated substantial progress in gene editing, designated pathogen-free breeding, and translational research. However, clinical success requires region-specific immunosuppressive protocols, pharmacogenomic adaptation, endemic infectious disease surveillance, and culturally sensitive public engagement. Regional collaboration through harmonized regulatory frameworks, multinational trial networks, and equitable access models will be essential to ensure that xenotransplantation benefits all Asian populations. This review proposes a distinct "Asian way" that integrates scientific excellence with cultural diversity and regional solidarity to shape the future of transplantation medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.